首页 > 市场调查报告书 > 製药

开发平台分析

市场调查报告书

商品编码

1550617

标籤先天性黑蒙市场：依治疗类型、依目标基因、依最终用户、按地区

Leber Congenital Amaurosis Market, By Treatment Type, By Target Gene, By End User, By Geography

出版日期: 2024年08月19日 | 出版商:

Coherent Market Insights | 英文 140 Pages | 商品交期: 2-3个工作天内

价格

简介目录

预计2024年全球先天性黑蒙市场规模为12.3亿美元，预计2031年将达16.8亿美元，2024年至2031年复合年增长率为4.5%。

报告范围		报告详情
基准年	2023年	2024年市场规模	12.3亿美元
实际资料	2019年至2023年	预测期	从2024年到2031年
预测 2024-2031 年复合年增长率：	4.50%	2031年价值预测	16.8亿美元

图：2024 年各地区标示先天性黑蒙市场占有率(%)

莱伯先天性黑蒙（LCA）是一群遗传性视网膜疾病，从出生起就会导致严重的视力障碍。其特征是视力下降和眼球震颤，并可能导致失明。 LCA 通常是由控制光感受器发育和视网膜色素上皮功能的基因突变引起的。由于感光细胞进行性退化，患者会遭受严重的视力丧失和失明。目前，LCA 尚无有效治疗方法。然而，基因疗法和视网膜假体装置有可能改善受影响个体的视力。由于新治疗剂和设备的开发，LCA 的全球市场预计在未来几年将显着成长。

市场动态：

全球标籤先天性黑蒙市场受到多种因素的推动，包括遗传性视网膜疾病发病率的上升、基因治疗产品和视网膜假体设备管道的扩大以及政府和非营利组织研究经费的增加，预计将经历高速成长。然而，目前，缺乏核准的治疗方案以及基因和细胞治疗的高成本可能会阻碍市场成长。从积极的一面来看，正在进行的评估基因疗法的临床试验和提高疾病管理意识正在为市场创造重大机会。

本研究的主要特点

该报告对全球标籤先天性黑蒙市场进行了详细分析，并提供了以2023年为基准年的预测期（2024-2031年）的市场规模（十亿美元）和年复合成长率（CAGR%）。

它还揭示了各个细分市场的潜在商机，并说明了该市场有吸引力的投资提案矩阵。

它还提供了对市场驱动因素、阻碍因素、机会、新产品发布和核准、市场趋势、主要企业采取的竞争策略等的重要见解。

本研究涵盖的主要企业包括 Spark Therapeutics、MeiraGTx Holdings plc、AGTC 和 ProQR Therapeutics NV。

该报告的见解使负责人和公司经营团队能够就未来的产品发布、升级、市场扩张和行销策略做出明智的决策。

全球标籤先天性黑蒙市场报告迎合了该行业的各个相关人员，如投资者、供应商、产品製造商、经销商、新进入者和财务分析师。

透过用于分析全球标籤先天性黑蒙市场的各种策略矩阵，将促进相关人员的决策。

Report Coverage	Report Details
Base Year:	2023	Market Size in 2024:	US$ 1.23 Bn
Historical Data for:	2019 To 2023	Forecast Period:	2024 To 2031
Forecast Period 2024 to 2031 CAGR:	4.50%	2031 Value Projection:	US$ 1.68 Bn

Leber congenital amaurosis (LCA) is a group of inherited retinal diseases causing severe visual impairment from birth. It is characterized by poor vision, nystagmus, and potentially blindness. LCA is typically caused due to mutations in genes responsible for photoreceptor development and retinal pigment epithelium function. As a result of progressive degeneration of photoreceptor cells, patients suffer from severe visual loss and blindness. Currently, there are no effective treatment options for LCA. However, gene therapy and retinal prosthetic devices hold promise to improve vision in affected individuals. The global LCA market is poised to grow significantly over the coming years driven by the development of novel therapeutics and devices.

Market Dynamics:

The global Leber congenital amaurosis market is projected to witness high growth over the next decade owing to several factors such as rising incidence of genetic retinal disorders, growing pipeline of gene therapy products and retinal prosthetic devices, and increasing research funding from government and non-profit organizations. However, lack of approved treatment options currently along with high cost of gene and cell-based therapies can hamper market growth. On the positive side, ongoing clinical trials evaluating gene therapies and increasing awareness about disease management provide significant opportunities in the market.

Key features of the study:

This report provides in-depth analysis of the global Leber congenital amaurosis market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, and competitive strategies adopted by key players

Key companies covered as part of this study include Spark Therapeutics, MeiraGTx Holdings plc, AGTC, ProQR Therapeutics N.V.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global Leber congenital amaurosis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Leber congenital amaurosis market

Detailed Segmentation-

By Treatment Type Insights (Revenue, USD Bn, 2019 - 2031)
- Gene Therapy
- Pharmaceutical Drugs
- Retinal Prosthesis
- Assistive Devices
- Others
By Target Gene Insights (Revenue, USD Bn, 2019 - 2031)
- RPE65
- GUCY2D
- AIPL1
- RPGRIP1
- CEP290
- Other Genes
By End-user Insights (Revenue, USD Bn, 2019 - 2031)
- Hospitals
- Specialized Eye Clinics
- Ophthalmology Research Centers
- Home Care Settings
- Others
By Regional Insights (Revenue, USD Bn, 2019 - 2031)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Novartis
- Biogen
- Spark Therapeutics
- GenSight Biologics
- Roche
- AbbVie
- Regeneron Pharmaceuticals
- Pfizer
- Astellas Pharma
- Santen Pharmaceutical
- Orphan Biovitrum
- Apellis Pharmaceuticals
- Gilead Sciences
- Eyenovia
- Avexis
- Regenxbio
- Horizon Therapeutics
- Aerie Pharmaceuticals
- Ophthotech Corporation
- Aldeyra Therapeutics

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Leber Congenital Amaurosis Market, By Treatment Type
- Global Leber Congenital Amaurosis Market, By Target Gene
- Global Leber Congenital Amaurosis Market, By End User
- Global Leber Congenital Amaurosis Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Global Leber Congenital Amaurosis Market, By Treatment Type, 2024-2031, (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Gene Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Pharmaceutical Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Retinal Prosthesis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Assistive Devices
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

5. Global Leber Congenital Amaurosis Market, By Target Gene, 2024-2031, (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
RPE65
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
GUCY2D
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
AIPL1
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
RPGRIP1
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
CEP290
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Other Genes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Leber Congenital Amaurosis Market, By End-User, 2024-2031, (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Specialized Eye Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Ophthalmology Research Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Home Care Settings
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Leber Congenital Amaurosis Market, By Region, 2019 - 2031, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2024,2027 & 2031, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2019 - 2031, Value (USD Bn)
- Regional Trends
  - North America
- Introduction
- Market Size and Forecast, By Treatment Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Target Gene, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By End-User, 2019 - 2031, Value (USD Bn)
U.S.
Canada
Latin America
- Introduction
- Market Size and Forecast, By Treatment Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Target Gene, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By End-User, 2019 - 2031, Value (USD Bn)
Brazil
Argentina
Mexico
Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Treatment Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Target Gene, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By End-User, 2019 - 2031, Value (USD Bn)
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Treatment Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Target Gene, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By End-User, 2019 - 2031, Value (USD Bn)
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Treatment Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Target Gene, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By End-User, 2019 - 2031, Value (USD Bn)
GCC Countries
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Treatment Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Target Gene, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By End-User, 2019 - 2031, Value (USD Bn)
South Africa
North Africa
Central Africa

8. Competitive Landscape

Novartis
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Biogen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Spark Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
GenSight Biologics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Roche
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AbbVie
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Regeneron Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Pfizer
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Astellas Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Santen Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Orphan Biovitrum
Apellis Pharmaceuticals
Gilead Sciences
Eyenovia
Avexis
Regenxbio
Horizon Therapeutics
Aerie Pharmaceuticals
Ophthotech Corporation
Aldeyra Therapeutics

9. Analyst Recommendations

Wheel of Fortune
Analyst View
Coherent Opportunity Map

10. References and Research Methodology

References
Research Methodology
About us

02-2729-4219

+886-2-2729-4219

License/价格

标籤先天性黑蒙市场：依治疗类型、依目标基因、依最终用户、按地区